Chronic Hepatitis News

Revision of standard upper limits of normal to age-specific and sex-specific alanine aminotransferase parameters in children with chronic hepatitis B highlighted ALT fluctuations during childhood and indeterminate HBV classification, according to recently published data.

Daklinza with Sovaldi and ribavirin produced similar rates of sustained virologic response among patients with hepatitis C genotypes 2 and 3 as those treated with Epclusa, according to a recently published study.

Fresenius Kidney Care developed a hepatitis C eradication program that resulted in a 97% cure rate among patients on dialysis who received direct-acting antiviral therapy.

The Chinese Food and Drug Administration added Ascletis’ hepatitis C NS5A inhibitor ravidasvir to the list of proposed priority review to accelerate its new drug application process, according to a press release.

This year at the American College of Gastroenterology Annual Meeting, several hepatology specialists discussed the changing landscape of liver disease health care, such as increasing rates of nonalcoholic fatty liver disease which is quickly becoming the number one indication for liver transplantation.

The Canadian Minister of Health announced that the Government of Canada will fund 28 projects across the country designed to reduce the risk for bloodborne infections, such as hepatitis C and HIV, among people who use injection drugs, according to a press release.

PHILADELPHIA – The direct-acting antiviral Vosevi demonstrated an average sustained virologic response rate of 87% among patients who were “triple-infected” with hepatitis C genotype 3, hepatitis B and HIV, as presented at the American College of Gastroenterology Annual Meeting.

PHILADELPHIA — Early detection of liver-related complications and hepatic diseases in patients who are pregnant leads to reduced risks and improved outcomes for both mother and child, according to a presentation at the American College of Gastroenterology Annual Meeting.

Experts in a recent review stated that an effective hepatitis C vaccine is critical for significant global control of the infection in combination with increased screening and treatment.

Janssen Pharmaceuticals entered into an agreement with Arrowhead Pharmaceuticals for an exclusive, worldwide license to develop and commercialize ARO-HBV, a phase 1/2 subcutaneous ribonucleic acid interference therapy for hepatitis B, according to a press release.